A cholecystokinin B receptor antagonist and cocaine interaction, phase I study
Abstract
RPR 102681, a cholecystokinin‐B antagonist, increased dopamine (DA) release and reduced cocaine self‐administration in animals. This pilot study sought to assess the safety and pharmacokinetics (PK) of co‐administration of RPR 102681 and cocaine, and to confirm the DA release mechanism of RPR 102681.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 20, 2018
- Source ID
- 10.1111/cns.12994
Entities
People
- Ahmed Elkashef
- Andrew Crabb
- Dean F. Wong
- Frank Vocci
- James Robert Brašić
- John Hilton
- Jurij Mojsiak
- Kimberly R. Warren
- Louis R. Cantelina Jr
- Nora Chiang
- Roberta Kahn
- Weiguo Ye
- Yun Zhou
Organizations
- Friends Research Institute
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins University
- Morgan State University
- National Institute on Drug Abuse
- Uniformed Services University of the Health Sciences